

RNS REACH: non-regulatory announcement



TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Investor Webinar

Alderley Park, UK - 26 March 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that Dr Huw Jones, Chief Executive Officer, and Dr Alastair Smith, Non-executive Chair, will be hosting an investor webinar on Wednesday, 2 April 2025 at 6.00 pm (BST).

The webinar is open to all existing and potential investors and will focus on the Company's plans to drive its Ox-1 addiction and SFX-01 glioblastoma programmes, following the fundraise which completed earlier this month. These funds will enable the Company to take the Orexin-1 antagonist to the key inflection point of clinical trial readiness, allowing it to unlock potential commercial opportunities.

There will be a Q&A session after the presentation and questions can be pre-submitted as part of the registration process. You can register for the event for free at:

<https://www.turnerpope.com/register/>

The webinar will be chaired by experienced news and corporate events presenter, Katie Pilbeam and hosted by TheraCryf's joint broker, Turner Pope Investments.

A more detailed presentation about Orexin-1, the market opportunity and the science behind the programme will be held in May.

Enquiries

TheraCryf plc

Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO

+44 (0)1625 315 090

enquiries@theracryf.com

Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker

+44 (0)20 3657 0050

Cavendish Capital Markets (NOMAD & Joint Broker)

Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

+44 (0)20 7220 0500

Vigo Consulting

Rozi Morris

+44 (0)20 7390 0231

theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well

partner its clinical programmes with mid size to large pharma for larger trials and commercialisation, as well as a number of industry partnerships with companies, including Stalicia SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park,Cheshire.It is quoted on AIM in London and trades under the ticker symbol TCF.

For further information, please visit: www.theracryf.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAXDSAFPSEFA